Home / Market News / $RMD
fiscal.ai Corporate Catalyst Impact 60/100 ● negative

ResMed Receives Analyst Downgrades from Morgans and Ord Minnett

Nov 4, 2026, 11:10 PM UTC · Primary ticker $RMD

ResMed Inc. has received analyst downgrades from 'Buy' to 'Accumulate' by Morgans and Ord Minnett. While the specific reasons for these adjustments were not disclosed, such downgrades typically signal a revised outlook on the company's growth prospects or valuation, potentially leading to short-term negative sentiment for the stock.

Morgans and Ord Minnett have downgraded their ratings for ResMed Inc. from 'Buy' to 'Accumulate'. This move, while not accompanied by detailed rationale in the provided report, suggests a more cautious outlook from these financial institutions regarding ResMed's stock performance. For traders, this could lead to short-term selling pressure as investors react to the revised recommendations. The long-term implications depend on the underlying reasons for the downgrades, which remain undisclosed, but it generally indicates a perceived reduction in the stock's upside potential or an increase in perceived risks. The key risk for traders is a potential dip in share price, while an opportunity might arise if the market overreacts and the fundamental business remains strong.

$RMD negative Analyst downgrades
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.